Literature DB >> 22915802

A safe foot-and-mouth disease vaccine platform with two negative markers for differentiating infected from vaccinated animals.

Sabena Uddowla1, Jason Hollister, Juan M Pacheco, Luis L Rodriguez, Elizabeth Rieder.   

Abstract

Vaccination of domestic animals with chemically inactivated foot-and-mouth disease virus (FMDV) is widely practiced to control FMD. Currently, FMD vaccine manufacturing requires the growth of large volumes of virulent FMDV in biocontainment-level facilities. Here, two marker FMDV vaccine candidates (A(24)LL3D(YR) and A(24)LL3B(PVKV)3D(YR)) featuring the deletion of the leader coding region (L(pro)) and one of the 3B proteins were constructed and evaluated. These vaccine candidates also contain either one or two sets of mutations to create negative antigenic markers in the 3D polymerase (3D(pol)) and 3B nonstructural proteins. Two mutations in 3D(pol), H(27)Y and N(31)R, as well as RQKP(9-12)→PVKV substitutions, in 3B(2) abolish reactivity with monoclonal antibodies targeting the respective sequences in 3D(pol) and 3B. Infectious cDNA clones encoding the marker viruses also contain unique restriction endonuclease sites flanking the capsid-coding region that allow for easy derivation of custom designed vaccine candidates. In contrast to the parental A(24)WT virus, single A(24)LL3D(YR) and double A(24)LL3B(PVKV)3D(YR) mutant viruses were markedly attenuated upon inoculation of cattle using the natural aerosol or direct tongue inoculation. Likewise, pigs inoculated with live A(24)LL3D(YR) virus in the heel bulbs showed no clinical signs of disease, no fever, and no FMD transmission to in-contact animals. Immunization of cattle with chemically inactivated A(24)LL3D(YR) and A(24)LL3B(PVKV)3D(YR) vaccines provided 100% protection from challenge with parental wild-type virus. These attenuated, antigenically marked viruses provide a safe alternative to virulent strains for FMD vaccine manufacturing. In addition, a competitive enzyme-linked immunosorbent assay targeted to the negative markers provides a suitable companion test for differentiating infected from vaccinated animals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915802      PMCID: PMC3486329          DOI: 10.1128/JVI.01254-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  A structural model of picornavirus leader proteinases based on papain and bleomycin hydrolase.

Authors:  T Skern; I Fita; A Guarné
Journal:  J Gen Virol       Date:  1998-02       Impact factor: 3.891

3.  [A study of the properties of attenuated cold variant of type O foot-and-mouth disease virus].

Authors:  S A Zhidkov; V A Sergeev
Journal:  Veterinariia       Date:  1969-10

4.  The development of an attenuated foot-and-mouth disease virus vaccine by modification and cloning in tissue cultures of BHK21 cells.

Authors:  G N Mowat; D A Barr; J H Bennett
Journal:  Arch Gesamte Virusforsch       Date:  1969

5.  Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK.

Authors:  A M King; B O Underwood; D McCahon; J W Newman; F Brown
Journal:  Nature       Date:  1981-10-08       Impact factor: 49.962

6.  Foot-and-mouth disease: the agar gel diffusion precipitin test for antibody to virus-infection-associated (via) antigen as a tool for epizootiologic surveys.

Authors:  J W McVicar; P Sutmoller
Journal:  Am J Epidemiol       Date:  1970-10       Impact factor: 4.897

7.  Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins.

Authors:  H G Berger; O C Straub; R Ahl; M Tesar; O Marquardt
Journal:  Vaccine       Date:  1990-06       Impact factor: 3.641

8.  Antiviral effects of a thiol protease inhibitor on foot-and-mouth disease virus.

Authors:  L G Kleina; M J Grubman
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice.

Authors:  E Rieder; T Bunch; F Brown; P W Mason
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

10.  Diagnosis of persistent aphthovirus infection and its differentiation from vaccination response in cattle by use of enzyme-linked immunoelectrotransfer blot analysis with bioengineered nonstructural viral antigens.

Authors:  I E Bergmann; P A de Mello; E Neitzert; E Beck; I Gomes
Journal:  Am J Vet Res       Date:  1993-06       Impact factor: 1.156

View more
  21 in total

1.  Infection and protection responses of deletion mutants of non-structural proteins of foot-and-mouth disease virus serotype Asia1 in guinea pigs.

Authors:  H Lalzampuia; Subhadra Elango; Jitendra K Biswal; Narayanan Krishnaswamy; R P Tamil Selvan; P Saravanan; Priyanka Mahadappa; G R Reddy; V Bhanuprakash; Aniket Sanyal; H J Dechamma
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-10       Impact factor: 4.813

2.  Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins.

Authors:  Anne Balkema-Buschmann; Kerstin Fischer; Leanne McNabb; Sandra Diederich; Nagendrakumar Balasubramanian Singanallur; Ute Ziegler; Günther M Keil; Peter D Kirkland; Maren Penning; Balal Sadeghi; Glenn Marsh; Jennifer Barr; Axel Colling
Journal:  Microorganisms       Date:  2022-05-25

3.  The C3d-fused foot-and-mouth disease vaccine platform overcomes maternally-derived antibody interference by inducing a potent adaptive immunity.

Authors:  Min Ja Lee; Hyun Mi Kim; Sehee Shin; Hyundong Jo; So Hui Park; Su-Mi Kim; Jong-Hyeon Park
Journal:  NPJ Vaccines       Date:  2022-06-28       Impact factor: 9.399

4.  Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus.

Authors:  Hiep L X Vu; Byungjoon Kwon; Marcelo de Lima; Asit K Pattnaik; Fernando A Osorio
Journal:  Vaccine       Date:  2013-07-23       Impact factor: 3.641

5.  Modification of the internal ribosome entry site element impairs the growth of foot-and-mouth disease virus in porcine-derived cells.

Authors:  Chao Sun; Decheng Yang; Rongyuan Gao; Te Liang; Haiwei Wang; Guohui Zhou; Li Yu
Journal:  J Gen Virol       Date:  2016-01-20       Impact factor: 3.891

6.  Repeated exposure to 5D9, an inhibitor of 3D polymerase, effectively limits the replication of foot-and-mouth disease virus in host cells.

Authors:  Devendra K Rai; Elizabeth A Schafer; Kamalendra Singh; Mark A McIntosh; Stefan G Sarafianos; Elizabeth Rieder
Journal:  Antiviral Res       Date:  2013-04-08       Impact factor: 5.970

7.  A continuous bovine kidney cell line constitutively expressing bovine αvβ6 integrin has increased susceptibility to foot-and-mouth disease virus.

Authors:  Michael LaRocco; Peter W Krug; Ed Kramer; Zaheer Ahmed; Juan M Pacheco; Hernando Duque; Barry Baxt; Luis L Rodriguez
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

8.  Requirements for improved vaccines against foot-and-mouth disease epidemics.

Authors:  Jong-Hyeon Park
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

9.  Antigenic properties and virulence of foot-and-mouth disease virus rescued from full-length cDNA clone of serotype O, typical vaccine strain.

Authors:  Rae-Hyung Kim; Jia-Qi Chu; Jeong-Nam Park; Seo-Yong Lee; Yeo-Joo Lee; Mi-Kyeong Ko; Ji-Hyeon Hwang; Kwang-Nyeong Lee; Su-Mi Kim; Dongseob Tark; Young-Joon Ko; Hyang-Sim Lee; Min-Goo Seo; Min-Eun Park; Byounghan Kim; Jong-Hyeon Park
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

10.  Evaluation of a 3A-truncated foot-and-mouth disease virus in pigs for its potential as a marker vaccine.

Authors:  Pinghua Li; Zengjun Lu; Xingwen Bai; Dong Li; Pu Sun; Huifang Bao; Yuanfang Fu; Yimei Cao; Yingli Chen; Baoxia Xie; Hong Yin; Zaixin Liu
Journal:  Vet Res       Date:  2014-05-01       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.